A new trading day began on Monday, with Humacyte Inc (NASDAQ: HUMA) stock price down -4.68% from the previous day of trading, before settling in for the closing price of $4.49. HUMA’s price has ranged from $2.43 to $9.97 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -26.44%. With a float of $103.71 million, this company’s outstanding shares have now reached $128.67 million.
Let’s determine the extent of company efficiency that accounts for 183 employees. In terms of profitability, gross margin is 35.2%, operating margin of -1042.56%, and the pretax margin is -1416.75%.
Humacyte Inc (HUMA) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Humacyte Inc is 19.40%, while institutional ownership is 27.88%. The most recent insider transaction that took place on Nov 19 ’24, was worth 7,979. In this transaction President, CEO and Director of this company bought 1,797 shares at a rate of $4.44, taking the stock ownership to the 243,851 shares. Before that another transaction happened on Nov 19 ’24, when Company’s Director bought 1,797 for $4.44, making the entire transaction worth $7,979. This insider now owns 243,851 shares in total.
Humacyte Inc (HUMA) Recent Fiscal highlights
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.26 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -26.44% per share during the next fiscal year.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
Here are Humacyte Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.34, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.86 in one year’s time.
Technical Analysis of Humacyte Inc (HUMA)
Looking closely at Humacyte Inc (NASDAQ: HUMA), its last 5-days average volume was 2.85 million, which is a jump from its year-to-date volume of 2.42 million. As of the previous 9 days, the stock’s Stochastic %D was 15.91%. Additionally, its Average True Range was 0.40.
During the past 100 days, Humacyte Inc’s (HUMA) raw stochastic average was set at 2.30%, which indicates a significant decrease from 6.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.60% in the past 14 days, which was lower than the 94.37% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.29, while its 200-day Moving Average is $5.41. However, in the short run, Humacyte Inc’s stock first resistance to watch stands at $4.54. Second resistance stands at $4.80. The third major resistance level sits at $4.96. If the price goes on to break the first support level at $4.12, it is likely to go to the next support level at $3.96. Now, if the price goes above the second support level, the third support stands at $3.70.
Humacyte Inc (NASDAQ: HUMA) Key Stats
With a market capitalization of 550.70 million, the company has a total of 125,859K Shares Outstanding. Currently, annual sales are 0 K while annual income is -110,780 K. The company’s previous quarter sales were 0 K while its latest quarter income was -39,200 K.
